| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
124,070,000 |
| Market
Cap: |
137.72(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.5599 - $6.19 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seres Therapeutics is a microbiome therapeutics platform company developing live biotherapeutic drugs. SER-109, Co.'s lead clinical candidate is an oral, purified bacterial spore-based microbiome therapeutic candidate consisting of a consortium of purified Firmicutes spores. Using Co.'s microbiome therapeutics platform, Co. is also developing SER-287 and SER-301 to treat ulcerative colitis. Co. evaluates microbiome pharmacokinetic and pharmacodynamic data from across its clinical and pre-clinical portfolios using its reverse translation microbiome therapeutics capabilities to conduct research on various indications, including inflammatory and immune diseases, cancer, and metabolic diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
8,738,243 |
| Total Buy Value |
$0 |
$0 |
$0 |
$27,525,465 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
36,381 |
36,381 |
71,150 |
83,200 |
| Total Sell Value |
$39,292 |
$39,292 |
$86,229 |
$162,501 |
| Total People Sold |
7 |
7 |
8 |
8 |
| Total Sell Transactions |
7 |
7 |
15 |
17 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Desrosier Thomas |
Chief Legal Officer and EVP |
• – – |
2023-10-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,501 |
118,047 |
|
- |
|
| Ege David S. |
See Remarks |
• – – |
2023-10-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,361 |
71,057 |
|
- |
|
| Cloghessy Paula |
See Remarks |
• – – |
2023-10-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,418 |
48,588 |
|
- |
|
| Shaff Eric D. |
CEO and President |
• • – |
2023-10-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
27,838 |
124,172 |
|
- |
|
| Von Moltke Lisa |
See Remarks |
• – – |
2023-10-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,745 |
13,745 |
|
- |
|
| Ege David S. |
See Remarks |
• – – |
2023-04-28 |
4 |
AS |
$5.19 |
$36,527 |
D/D |
(7,038) |
59,696 |
|
-34% |
|
| Arkowitz David |
Chief Financial Officer |
• – – |
2023-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
42,500 |
166,613 |
|
- |
|
| Ege David S. |
See Remarks |
• – – |
2023-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
66,734 |
|
- |
|
| Ege David S. |
See Remarks |
• – – |
2022-10-31 |
4 |
AS |
$7.93 |
$39,745 |
D/D |
(5,012) |
46,734 |
|
-37% |
|
| Arkowitz David |
Chief Financial Officer |
• – – |
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
42,500 |
112,992 |
|
- |
|
| Ege David S. |
See Remarks |
• – – |
2022-10-27 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
51,746 |
|
- |
|
| Flagship Pioneering Fund Vii, L.p. |
10% Owner |
– – • |
2022-07-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,825,495 |
|
87% |
|
| Afeyan Noubar |
10% Owner |
– – • |
2022-07-05 |
4 |
B |
$3.15 |
$27,525,465 |
I/I |
8,738,243 |
5,825,495 |
1.5 |
87% |
|
| Arkowitz David |
Chief Financial Officer |
• – – |
2022-07-05 |
4 |
A |
$3.15 |
$200,000 |
D/D |
63,492 |
65,492 |
|
- |
|
| Ege David S. |
See Remarks |
• – – |
2022-07-05 |
4 |
A |
$3.15 |
$100,000 |
D/D |
31,746 |
31,746 |
|
- |
|
| Kender Richard N |
Director |
– • – |
2022-07-05 |
4 |
A |
$3.15 |
$200,000 |
D/D |
63,492 |
63,492 |
|
- |
|
| Desrosier Thomas |
Chief Legal Officer and EVP |
• – – |
2022-07-05 |
4 |
A |
$3.15 |
$200,000 |
D/D |
63,492 |
104,546 |
|
- |
|
| Dere Willard H |
Director |
– • – |
2022-07-05 |
4 |
A |
$3.15 |
$100,000 |
D/D |
31,746 |
31,746 |
|
- |
|
| Biondi Paul |
Director |
– • – |
2022-07-05 |
4 |
A |
$3.15 |
$150,000 |
D/D |
47,619 |
47,619 |
|
- |
|
| Shaff Eric D. |
CEO and President |
• • – |
2022-07-05 |
4 |
A |
$3.15 |
$200,000 |
D/D |
63,492 |
96,334 |
|
- |
|
| Henn Matthew R. |
See Remarks |
• – – |
2022-07-05 |
4 |
A |
$3.15 |
$150,000 |
D/D |
47,619 |
47,619 |
|
- |
|
| Cloghessy Paula |
See Remarks |
• – – |
2022-07-05 |
4 |
A |
$3.15 |
$100,000 |
D/D |
31,746 |
31,746 |
|
- |
|
| Zausner Meryl |
Director |
– • – |
2022-07-05 |
4 |
A |
$3.15 |
$100,000 |
D/D |
31,746 |
31,746 |
|
- |
|
| Arkowitz David |
Chief Financial Officer |
• – – |
2022-06-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
70,492 |
|
- |
|
| Arkowitz David |
Chief Financial OfficerOfficer |
• – – |
2021-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,000 |
|
-68% |
|
195 Records found
|
|
Page 2 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.08 (6.72%) 
